WitrynaItem Name IMWITOR® 742 Product Specification PP-0027 Characteristic Inspection Method Unit Specified Range Acid value Ph. Eur. 2.5.1 mg KOH / g <= 1 Saponification value Ph. Eur. 2.5.6 mg KOH / g 250 - 280 Water content Ph. Eur. 2.5.12 % <= 0,5 Iodine value* Ph. Eur. 2.5.4 g I/100g <= 1 Witryna18 cze 2004 · The most effective excipients with digoxin were (at 0.5%, w/v): Labrasol > Imwitor 742 > Acconon E = Softigen 767 > Cremophor EL > Miglyol > Solutol HS 15 > Sucrose monolaurate > Polysorbate 20 > TPGS > Polysorbate 80. With celiprolol, Cremophor EL and Acconon E had no effect, but transport was enhanced by Softigen …
IMWITOR® Cosmetics Ingredients by IOI Oleo - SpecialChem
WitrynaTrade name: IMWITOR 742 (Contd. of page 1) • Precautionary statements . P280 Wear protective gloves/protective clothing/eye protection/face protection. P332+P313 If skin irritation occurs: Get medical advice/attention. P362 Take off contaminated clothing and wash before reuse. P302+P352 IF ON SKIN: Wash with plenty of soap and water. • WitrynaIMWITOR® Highly functionalized lipids for drug delivery systems MIGLYOL® Reference-quality C8 – C10 esters for pharma formulations SOFTIGEN® Compendial liquid solubilizer SOFTISAN® Specialties for topical and oral applications WITEPSOL® Benchmark hard fats for suppositories and ovules binishi wireless headphones review
IOI Oleo GmbH PharmaCentral Materials and Knowledge Platform
WitrynaWith celiprolol, Cremophor EL and Acconon E had no effect, but transport was enhanced by Softigen 767 > TPGS > Imwitor 742. In vivo, the excipients changed the pharmacokinetic profile of orally administered digoxin or celiprolol, but without increasing the overall AUC. The most consistent change was an early peak of absorption, … Witryna1 maj 2007 · The supercooled liquid state of Imwitor 742 was quite stable. However, additives to retard crystallization should be used, because the deviation in the … Witryna7 mar 2024 · IMWITOR 742® – The penetration enhancer and bioavailability booster for your API 7. March 2024 Improving bioavailability is a key challenge for formulators … binishofer